Cancer trials in sub-Saharan Africa: Aligning research and care

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr.

2. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3: 524–48. doi: 10.1001/jamaoncol.2016.5688 27918777

3. Kingham TP, Alatise OI, Vanderpuye V, Casper C, Abantanga FA, Kamara TB, et al. Treatment of cancer in sub-Saharan Africa. Lancet Oncol. 2013;14: e158–67. doi: 10.1016/S1470-2045(12)70472-2 23561747

4. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, et al. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol. 2009;27: 3480–8. doi: 10.1200/JCO.2008.18.7641 19470940

5. Olweny CL, Borok M, Gudza I, Clinch J, Cheang M, Kiire CF, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. 2005;113: 632–9. doi: 10.1002/ijc.20606 15472910

6. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60: 150–7. doi: 10.1097/QAI.0b013e318251aedd 22395672

7. Martin J, Laker-Oketta M, Walusansa V, et al. Randomized Trial of Protease Inhibitor-Based Antiretroviral Therapy for Kaposi Sarcoma in Africa. Paper presented at the Conference on Retroviruses and Opportunistic Infections; March 2014; Boston, MA.

8. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 2001;358: 404–9. 11502340

9. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360: 34–40. doi: 10.1016/S0140-6736(02)09330-3 12114039

10. Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist. 2016;21: 1113–20. doi: 10.1634/theoncologist.2015-0478 27185615

11. Shulman LN, Wagner CM, Barr R, Lopes G, Longo G, Robertson J, et al. Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes. J Clin Oncol. 2016;34: 69–75. doi: 10.1200/JCO.2015.61.8736 26578613

12. Kanavos P, Vandoros S, Garcia-Gonzalez P. Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. Global Health. 2009;5: 19. doi: 10.1186/1744-8603-5-19 20043820

13. Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, et al. Population pharmacokinetics of Reditux, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016;78: 353–9. doi: 10.1007/s00280-016-3083-x 27329361

14. Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA. 2016.

15. ClinicalTrials.gov. Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma in Malawi. https://clinicaltrials.gov/ct2/show/NCT02660710.

16. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's lymphoma. Lancet. 2012;379: 1234–44. doi: 10.1016/S0140-6736(11)61177-X 22333947

17. Hosseinipour MC, Sweet KM, Xiong J, Namarika D, Mwafongo A, Nyirenda M, et al. Viral profiling identifies multiple subtypes of Kaposi's sarcoma. MBio. 2014;5: e01633–14. doi: 10.1128/mBio.01633-14 25249280

18. Liu W, Snell JM, Jeck WR, Hoadley KA, Wilkerson MD, Parker JS, et al. Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. JCI Insight. 2016;1: e88755. doi: 10.1172/jci.insight.88755 27734031

19. Fedoriw Y, Montgomery N, Parker J et al. Immunophenotypic and Molecular Profiling of HIV-Associated Diffuse Large B-cell Lymphomas from sub-Saharan Africa. Paper presented at annual meeting of the United States & Canadian Academy of Pathology Annual Meeting; March 2016; Seattle, WA.

20. Molyneux E, Schwalbe E, Chagaluka G, Banda K, Israels T, Depani S, et al. The use of anthracyclines in the treatment of endemic Burkitt lymphoma. Br J Haematol. 2016 Nov 28. doi: 10.1111/bjh.14440. [Epub ahead of print] 27891583

21. Buckle G, Maranda L, Skiles J, Ong'echa JM, Foley J, Epstein M, et al. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study. Int J Cancer. 2016;139: 1231–40. doi: 10.1002/ijc.30170 27136063

22. Stanley CC, Westmoreland KD, Heimlich BJ, El-Mallawany NK, Wasswa P, Mtete I, et al. Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. Br J Haematol. 2016;173: 705–12. doi: 10.1111/bjh.13986 26914979

23. Harif M, Barsaoui S, Benchekroun S, Bouhas R, Doumbe P, Khattab M, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa—report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2008;50: 1138–42. doi: 10.1002/pbc.21452 18213709

24. Traore F, Coze C, Atteby JJ, Andre N, Moreira C, Doumbe P, et al. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2011;56: 70–6. doi: 10.1002/pbc.22746 21058286

25. Westmoreland KD, Montgomery ND, Stanley CC, El-Mallawany NK, Wasswa P, van der Gronde T, et al. Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis, and response assessment in Malawi. Int J Cancer. 2017;140: 2509–16 doi: 10.1002/ijc.30682 28268254

26. Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016;34: 2020–7. doi: 10.1200/JCO.2015.63.1119 27069074

27. Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016;374: 2419–29. doi: 10.1056/NEJMoa1510093 27332902

28. Rodriguez-Galindo C, Friedrich P, Alcasabas P, Antillon F, Banavali S, Castillo L, et al. Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge. J Clin Oncol. 2015;33: 3065–73. doi: 10.1200/JCO.2014.60.6376 26304881